Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Clinical Therapeutics|June 21, 2014
Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized studyRashmi Mehta, Kelly Hardes, Dennis Kelleher, et al.
Respiratory Medicine|April 14, 2012
A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPDJames F Donohue, Antonio Anzueto, Jean Brooks, et al.
Clinical Pharmacokinetics|July 20, 2019
Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary DiseaseRashmi Mehta, Colm Farrell, Siobhán Hayes, et al.
Journal of Clinical Pharmacology|July 16, 2024
Population Pharmacokinetic Analysis of Dolutegravir in Treatment-Experienced Adults Living with HIV-1Hardik Chandasana, Mark Bush, Mounir Ait-Khaled, et al.
Clinical Pharmacology : Advances and Applications|July 2, 2020
The Effect of Moderate- and High-Fat Meals on the Bioavailability of Dolutegravir/Rilpivirine Fixed-Dose Combination TabletRashmi Mehta, Joseph Piscitelli, Allen Wolstenholme, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|February 12, 2020
A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic-pituitary-adrenocortical axis of children with asthmaPhilippe Bareille, Susan Tomkins, Varsha Imber, et al.
Academic Radiology|April 13, 2021
Patient preferences regarding use of contrast-enhanced imaging for breast cancer screeningDaniel Son, Jordana Phillips, Tejas S Mehta, et al.
Respiratory Physiology & Neurobiology|October 3, 2012
Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patientsMarc Decramer, François Maltais, Gregory Feldman, et al.
Chest|January 4, 2014
Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled studyBartolome Celli, Glenn Crater, Sally Kilbride, et al.
Cureus|October 28, 2024
A New Purpose to Old Arsenal: Exploring the Safety and Efficacy of a New Regimen Comprising a Combination of Chlorhexidine Gluconate and Cetrimide for Seborrheic Dermatitis Treatment in a Randomized Placebo-Controlled Clinical TrialRashmi Mehta, Diamond Jain, Pratheesh N Prabhakaran, et al.
Pageof 6